BioCryst Pharmaceuticals, Inc.

555 articles with BioCryst Pharmaceuticals, Inc.

• CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

  3/8/2023

  BioCryst Pharmaceuticals, Inc. announced that the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee has issued a positive recommendation for ORLADEYO® to be reimbursed for the routine prevention of attacks of hereditary angioedema in adults and pediatric patients 12 years of age and older.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2023

  3/2/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 110,400 shares, and restricted stock units (RSUs) covering an aggregate of 51,300 shares, of BioCryst common stock.

• BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)

  2/24/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data from the APeX-S and APeX-2 clinical trials which evaluated oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE).

• BioCryst to Present at Upcoming Investor Conferences - February 22, 2023

  2/22/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Cowen 43rd Annual Health Care Conference in Boston, MA on Wednesday, March 8th at 12:50 p.m. ET and the Barclays 2023 Global Healthcare Conference in Miami, FL on Tuesday, March 14th at 9:30 a.m. ET.

• BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones

  2/21/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.

• BioCryst to Report Fourth Quarter 2022 Financial Results on February 21

  2/7/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2022 financial results on Tuesday, February 21, 2023.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 6, 2023

  2/6/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 20 newly-hired employees stock options to purchase an aggregate of 287,200 shares, and restricted stock units (RSUs) covering an aggregate of 101,700 shares, of BioCryst common stock.

• BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

  2/3/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held in San Antonio, Texas, from February 24-27, 2023.

• BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

  1/26/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the pivotal APeX-P trial evaluating oral, once-daily ORLADEYO ® (berotralstat) in pediatric hereditary angioedema (HAE) patients who are 2 to12 years of age.

• BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

  1/23/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO ® (berotralstat) in Central and Eastern Europe (CEE).

• BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

  1/9/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that initial data from ongoing phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trials in healthy volunteers show rapid, sustained and >97 percent suppression of the alternative pathway (AP) of the complement system 24 hours following a single 110 mg dose.

• BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

  1/9/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO® (berotralstat) net revenue for the fourth quarter and full year 2022 and provided guidance for full year 2023 ORLADEYO net revenue and expected peak ORLADEYO sales.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 05, 2023

  1/5/2023

  BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 178,100 shares, and restricted stock units covering an aggregate of 56,050 shares, of BioCryst common stock.

• BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 10, 2023, at 6:00 p.m. ET.

• 

  BioCryst Discontinues Mid-Stage Factor D Inhibitor

  12/15/2022

  BioCryst Pharmaceuticals is discontinuing the development of its Factor D inhibitor BCX9930 in paroxysmal nocturnal hemoglobinuria due to competitive factors.

• BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013

  12/15/2022

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, based on new competitive data recently presented at the American Society of Hematology (ASH) annual meeting, the company no longer believes that BCX9930 would be commercially competitive, and is discontinuing the development of BCX9930.

• BioCryst to Present at JMP Securities Hematology & Oncology Summit

  12/5/2022

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present virtually at the JMP Securities Hematology & Oncology Summit on Wednesday, December 7, 2022, at 11:40 a.m. ET.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 05, 2022

  12/5/2022

  BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 21 newly-hired employees stock options to purchase an aggregate of 134,600 shares, and restricted stock units covering an aggregate of 67,300 shares, of BioCryst common stock.

• BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health

  11/28/2022

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO ® (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Israel.

• BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy

  11/10/2022

  BioCryst Pharmaceuticals, Inc. announced new real-world data demonstrating rapid, sustained reduction of patient-reported HAE attacks and consistently low attack rates among patients 12 years and older who started on oral, once-daily ORLADEYO® for the prophylactic treatment of hereditary angioedema, including patients who switched from other prophylactic therapies.